Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Accumulated Depreciation (2016 - 2021)

vTv Therapeutics (VTVT) has disclosed Accumulated Depreciation for 8 consecutive years, with $305000.0 as the latest value for Q4 2021.

  • Quarterly Accumulated Depreciation rose 41.2% to $305000.0 in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $305000.0 through Dec 2021, up 41.2% year-over-year, with the annual reading at $305000.0 for FY2021, 41.2% up from the prior year.
  • Accumulated Depreciation hit $305000.0 in Q4 2021 for vTv Therapeutics, up from $216000.0 in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $9.1 million in Q4 2017 to a low of $148000.0 in Q4 2019.
  • Historically, Accumulated Depreciation has averaged $3.6 million across 5 years, with a median of $305000.0 in 2021.
  • Biggest five-year swings in Accumulated Depreciation: tumbled 98.24% in 2019 and later skyrocketed 45.95% in 2020.
  • Year by year, Accumulated Depreciation stood at $9.1 million in 2017, then dropped by 7.51% to $8.4 million in 2018, then crashed by 98.24% to $148000.0 in 2019, then soared by 45.95% to $216000.0 in 2020, then soared by 41.2% to $305000.0 in 2021.
  • Business Quant data shows Accumulated Depreciation for VTVT at $305000.0 in Q4 2021, $216000.0 in Q4 2020, and $148000.0 in Q4 2019.